Regeneron Pharmaceuticals (REGN) Construction in Progress (2013 - 2017)

Regeneron Pharmaceuticals' Construction in Progress history runs 5 years deep, the most recent figure standing at $408.9 million for Q4 2017.

• On a quarterly basis, Construction in Progress rose 28.2% year-over-year to $408.9 million in Q4 2017; TTM through Dec 2017 was $408.9 million, a 28.2% increase from a year earlier, with the FY2017 full-year figure at $408.9 million, up 28.2% from the prior year.
• Construction in Progress advanced to $408.9 million in Q4 2017 per REGN's latest filing, from $318.9 million in the prior quarter.
• Across five years, Construction in Progress topped out at $579.8 million in Q4 2015 and bottomed at $142.4 million in Q4 2013.
• The 5-year median for Construction in Progress is $408.9 million (2017), against an average of $384.4 million.
• Across the five-year window, Construction in Progress soared 231.69% in 2014 and plunged 45.0% in 2016, its largest moves.
• Year by year, Construction in Progress stood at $142.4 million in 2013, then surged by 231.69% to $472.2 million in 2014, then gained by 22.79% to $579.8 million in 2015, then plunged by 45.0% to $318.9 million in 2016, then advanced by 28.2% to $408.9 million in 2017.
• Per Business Quant, the three latest REGN Construction in Progress figures stand at $408.9 million (Q4 2017), $318.9 million (Q4 2016), and $579.8 million (Q4 2015).